Extension study to evaluate the safety and immunogenicity of a revaccination dose of the RSVPreF3 OA investigational vaccine in adults 60 years and older who participated in the RSV OA=ADJ-002 study

Trial Identifier: 213569
Sponsor: GlaxoSmithKline
Start Date: December 2020
Primary Completion Date: June 2021
Study Completion Date: October 2021
Condition: Respiratory Syncytial Virus Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Belgium Gent, Belgium, 9000
Belgium Leuven, Belgium, 3000
Belgium Wilrijk, Belgium, 2610
United States, Kansas Lenexa, Kansas, United States, 66219
United States, Maryland Elkridge, Maryland, United States, 21075
United States, Nebraska Omaha, Nebraska, United States, 68134
United States, New York Rochester, New York, United States, 14609
United States, North Carolina Hickory, North Carolina, United States, 28601
United States, South Carolina Mt. Pleasant, South Carolina, United States, 29464
United States, Texas San Antonio, Texas, United States, 78229